PL319600A1 - Spray-dried microparticles as therapeutic carriers - Google Patents

Spray-dried microparticles as therapeutic carriers

Info

Publication number
PL319600A1
PL319600A1 PL95319600A PL31960095A PL319600A1 PL 319600 A1 PL319600 A1 PL 319600A1 PL 95319600 A PL95319600 A PL 95319600A PL 31960095 A PL31960095 A PL 31960095A PL 319600 A1 PL319600 A1 PL 319600A1
Authority
PL
Poland
Prior art keywords
spray
dried microparticles
therapeutic carriers
carriers
therapeutic
Prior art date
Application number
PL95319600A
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of PL319600A1 publication Critical patent/PL319600A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL95319600A 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic carriers PL319600A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94307126 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Publications (1)

Publication Number Publication Date
PL319600A1 true PL319600A1 (en) 1997-08-18

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95319600A PL319600A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic carriers

Country Status (16)

Country Link
EP (1) EP0783298A1 (en)
JP (1) JPH10506406A (en)
KR (1) KR970705979A (en)
AU (1) AU701440B2 (en)
BR (1) BR9509171A (en)
CA (1) CA2199954A1 (en)
CZ (1) CZ92497A3 (en)
FI (1) FI971332A0 (en)
HU (1) HUT77373A (en)
MX (1) MX9702357A (en)
NO (1) NO971438D0 (en)
NZ (1) NZ292980A (en)
PL (1) PL319600A1 (en)
RU (1) RU2147226C1 (en)
WO (1) WO1996009814A1 (en)
ZA (1) ZA958239B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
JP4024302B2 (en) * 1996-05-17 2007-12-19 クアドラント、 ドラッグ、 デリバリー、 リミテッド Microparticles and their use in wound treatment
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9615435D0 (en) * 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
JP2002515887A (en) * 1996-10-19 2002-05-28 クウォドラント、ヘルスケアー、（ユーケー）、リミテッド Use of hollow microcapsules in diagnosis and therapy
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
US6077543A (en) * 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
ES2236832T3 (en) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology PREPARATION OF PARTICLES FOR INHALATION.
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1999016421A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
US20030021777A1 (en) * 1998-02-20 2003-01-30 Roy Harris Product comprising bound fibrinogen and thrombin for use in wound therapy or surgical repair
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
JP2002518432A (en) * 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド Large porous particles released from an inhaler
WO2000062819A1 (en) * 1999-04-21 2000-10-26 1355540 Ontario Inc. Formulations for detecting asthma
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
ATE297196T1 (en) 1999-12-20 2005-06-15 Nicholas J Kerkhof METHOD FOR PRODUCING NANOMETER PARTICLES BY FLUID BED SPRAY DRYING
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
JP2004521103A (en) 2000-12-21 2004-07-15 ネクター セラピューティックス Storage stable powder composition of interleukin 4 receptor
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
US8524279B2 (en) 2001-11-01 2013-09-03 Novartis Ag Spray drying methods and related compositions
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003299795A1 (en) 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
JP2007500234A (en) 2003-05-28 2007-01-11 ネクター セラピューティクス Pharmaceutical moldings containing active agents insoluble in water
RU2426590C2 (en) 2003-07-18 2011-08-20 Бакстер Интернэшнл Инк. Method of production, use and composition of minor spherical particles produced in controlled phase separation
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
EP3590503A1 (en) 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
UA90013C2 (en) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
EP2349219A4 (en) * 2008-09-29 2013-05-01 Univ Mercer Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (en) 2009-02-06 2010-08-11 ProFibrix BV Biodegradable extravascular support
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
PL2435028T3 (en) * 2009-05-28 2017-09-29 Profibrix Bv Dry powder fibrin sealant
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
NZ600812A (en) 2010-01-08 2014-08-29 Profibrix Bv Dry powder fibrin sealant
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
BR112013010926A2 (en) 2010-11-01 2016-08-23 Univ Technology Sidney immunomodulatory agents and their uses
EP3225235B1 (en) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
CN105853348B (en) 2011-03-10 2019-08-30 Xeris药物公司 Parenteral injection stablizing solution
RU2013155713A (en) 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
MX349383B (en) 2011-10-31 2017-07-26 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes.
CN104470503A (en) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 Aggregate particles
IN2014DN10714A (en) * 2012-06-26 2015-09-04 Ge Healthcare As
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
ES2752021T3 (en) 2013-02-01 2020-04-02 Glialogix Inc Compositions and methods for the treatment of neurodegenerative diseases and other diseases
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CA2926719C (en) 2013-10-08 2020-11-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3125875B1 (en) 2014-04-04 2023-06-07 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
ES2936067T3 (en) 2014-05-27 2023-03-14 Univ Queensland IL-22 for use in the treatment of metabolic disorders
JP6982495B2 (en) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド Syringes, kits, and methods for intradermal and / or subcutaneous injection of paste
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
EP3307295A1 (en) 2015-06-10 2018-04-18 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
BR112019024987A2 (en) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. SMALL MOLECULE DRUG FORMULATIONS RESISTANT TO PRECIPITATION
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100277622B1 (en) * 1992-06-12 2001-01-15 이타가키 히로시 Inhalation ultrafine powder and its manufacturing method
EP0606486B1 (en) * 1992-06-12 2001-08-29 Teijin Limited Pharmaceutical preparation for intra-airway administration

Also Published As

Publication number Publication date
NO971438L (en) 1997-03-26
BR9509171A (en) 1997-09-16
FI971332A (en) 1997-04-01
RU2147226C1 (en) 2000-04-10
EP0783298A1 (en) 1997-07-16
NZ292980A (en) 1999-02-25
FI971332A0 (en) 1997-04-01
ZA958239B (en) 1996-09-30
KR970705979A (en) 1997-11-03
AU701440B2 (en) 1999-01-28
CZ92497A3 (en) 1997-08-13
AU3530295A (en) 1996-04-19
JPH10506406A (en) 1998-06-23
NO971438D0 (en) 1997-03-26
MX9702357A (en) 1997-06-28
CA2199954A1 (en) 1996-04-04
WO1996009814A1 (en) 1996-04-04
HUT77373A (en) 1998-03-30

Similar Documents

Publication Publication Date Title
PL319600A1 (en) Spray-dried microparticles as therapeutic carriers
PL329720A1 (en) Microparticles
ZA975040B (en) Spray-drying process
DE69515496D1 (en) Laseradressierbare thermographische elemente
GB9607035D0 (en) Spray-dried microparticles as therapeutic vehicles
GB9419021D0 (en) Therapeutic protein
ZA978359B (en) Novel treatment
GB9410512D0 (en) Novel treatment
EP0797446A4 (en) Cd40 associated proteins
GB9615767D0 (en) Novel treatment
GB9411635D0 (en) Novel treatment
ZA977005B (en) Therapeutic uses
GB9625795D0 (en) Novel treatment
TW295046U (en) Improved caster
GB9721692D0 (en) Novel treatment
GB9612752D0 (en) Novel treatment
ZA959458B (en) Pharmaceutical carriers
GB9404379D0 (en) Therapeutic improvement
GB9420340D0 (en) Therapeutic improvement
GB9407105D0 (en) Liver disease treatment
GB9608230D0 (en) Physiological supports
ZA959331B (en) Therapeutic protein
GB9721693D0 (en) Novel treatment
GB9407717D0 (en) Physiological supports
TW306269U (en) Nursing bottle structure improvement